title: [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
abstract: Reasons for using TNFalpha inhibitors in rheumatoid arthritis Available agents modulating TNFalpha Adverse effects to TNFalpha inhibitors Which patients should be treated with TNFalpha inhibitors? Monitoring treatment with TNFalpha inhibitors Patient follow-up Open questions Conclusions
authors: Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, CHU, 371, avenue du Doyen-Gaston-Giraud, 34295 Montpellier Cedex 5, France. j-sany@chu-montpellier.fr
authors: Jacques
authors: J
authors: Sany
authors: Marie-Joëlle
authors: MJ
authors: Kaiser
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001986:Bronchial Spasm / Q000209:etiology; D000068800:Etanercept; D006261:Headache / Q000209:etiology; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014581:Urticaria / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept